STAAR Surgical (STAA) Stock Forecast & Price Target

Staar Surgical is supported by a strong China recovery, with 2Q’26 net sales of $93.5M, up 111.0% year over year, as EVO+ adoption accelerated and management reported no evidence of distributor inventory build. Profitability is inflecting sharply, as adj. EBITDA reached $20.0M, or a 21.4% margin, versus a prior-year loss, helped by 74.5% gross margin, disciplined operating expense control, and lower manufacturing and freight costs. The leadership transition to permanent CEO Warren Foust, combined with a debt-free balance sheet and $181.5M in cash and investments, removes an overhang while leaving ample flexibility to fund infrastructure investment and sustain long-term growth.

Staar Surgical is facing a weaker fundamental backdrop because its core ICL franchise is showing only a partial recovery in China, where annual growth has slowed to 3%-5% from the 10-20% pace seen in 2016-2019, indicating demand remains below the pre-COVID trend. The cited ophthalmologist’s comments suggest the product still has strong clinical preference versus LASIK, SMILE, and PRK, but affordability pressure in a soft China macro environment is pushing price-sensitive patients toward lower-cost alternatives, limiting volume acceleration. With almost all revenue tied to ICL sales and foreign markets, even a modestly lower revenue expectation for FY’26 and a re-weighted scenario outlook point to vulnerable fundamentals and constrained upside.